Table 4.
Eyelash characteristics: mean raw values ± SD at baseline and months 4 and 6 (intent‐to‐treat population)
| Efficacy end point | Time point | Idiopathic hypotrichosis bimatoprost 0·03% (n = 179) | Idiopathic hypotrichosis vehicle (n = 59) |
|---|---|---|---|
| Upper eyelash length (mm) | Baseline | 5·69 ± 0·90 (177) | 5·83 ± 0·67 (58) |
| Month 4 | 6·94 ± 1·28 (177) | 5·53 ± 0·80 (59) | |
| Month 6 | 7·12 ± 1·32 (177) | 5·75 ± 0·80 (59) | |
| Upper eyelash thickness (mm2) | Baseline | 0·79 ± 0·34 (150) | 0·87 ± 0·36 (52) |
| Month 4 | 1·33 ± 0·55 (162) | 0·78 ± 0·37 (53) | |
| Month 6 | 1·30 ± 0·50 (165) | 0·77 ± 0·38 (55) | |
| Upper eyelash darknessa (intensity units) | Baseline | 149·29 ± 23·90 (150) | 143·49 ± 24·78 (52) |
| Month 4 | 125·39 ± 25·88 (162) | 143·73 ± 24·31 (53) | |
| Month 6 | 127·95 ± 26·39 (165) | 146·08 ± 24·24 (55) |
| Efficacy end point | Time point | Chemotherapy‐induced hypotrichosis subjects receiving bimatoprost 0·03% (n = 96) | Chemotherapy‐induced hypotrichosis subjects receiving vehicle (n = 34) |
|---|---|---|---|
| Upper eyelash length (mm) | Baseline | 4·87 ± 1·20 (94) | 4·65 ± 1·41 (31) |
| Month 4 | 6·32 ± 1·46 (96) | 5·34 ± 1·20 (33) | |
| Month 6 | 6·84 ± 1·49 (96) | 5·61 ± 1·12 (33) | |
| Upper eyelash thickness (mm2) | Baseline | 0·39 ± 0·30 (66) | 0·67 ± 0·10 (19) |
| Month 4 | 1·01 ± 0·50 (80) | 0·63 ± 0·37 (28) | |
| Month 6 | 1·18 ± 0·59 (84) | 0·72 ± 0·41 (28) | |
| Upper eyelash darkness (intensity units)a | Baseline | 156·16 ± 25·91 (65) | 164·22 ± 25·65 (18) |
| Month 4 | 138·41 ± 25·53 (82) | 149·07 ± 22·70 (28) | |
| Month 6 | 132·65 ± 25·71 (85) | 148·50 ± 20·86 (28) |
Values are given as mean ± SD (n). Bimatoprost 0·03%, bimatoprost ophthalmic solution 0·03%. aA negative change from baseline indicates darker eyelashes compared with baseline.